Danish diabetes powerhouse Novo Nordisk A/S delivered record Japan sales of 89 billion yen in 2015, up 6% over the previous year, buoyed by its long-acting insulin analog Tresiba (insulin degludec) and Victoza (liraglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist,…
To read the full story
Related Article
- Novo Japan Chalks Up Record Sales in 2016 on Tresiba, Victoza
April 13, 2017
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
BUSINESS
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Healios to File MultiStem in Japan Without Waiting for PIII Results: CEO
August 17, 2026
- Taiho’s Zipalertinib Hits Primary Goal in 1st Line NSCLC Trial
August 17, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





